Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.

× No keyword cloud information.

13 in total

1. The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.

Authors: Yunjuan Gu; Xuhong Hou; Lei Zhang; Jiemin Pan; Qingxia Cai; Yuqian Bao; Weiping Jia
Journal: Diabetes Technol Ther Date: 2011-11-02 Impact factor: 6.118

2. Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.

Authors: Daisuke Fujiwara; Kenji Takahashi; Takahiro Suzuki; Masakazu Shii; Yukako Nakashima; Sato Takekawa; Atsushi Yoshida; Takashi Matsuoka
Journal: J Diabetes Investig Date: 2013-05-30 Impact factor: 4.232

3. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

Authors: J Rosenstock; A Jelaska; C Zeller; G Kim; U C Broedl; H J Woerle
Journal: Diabetes Obes Metab Date: 2015-07-14 Impact factor: 6.577

4. Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years.

Authors: Anita Lynam; Timothy McDonald; Anita Hill; John Dennis; Richard Oram; Ewan Pearson; Michael Weedon; Andrew Hattersley; Katharine Owen; Beverley Shields; Angus Jones
Journal: BMJ Open Date: 2019-09-26 Impact factor: 2.692

Review 5. Insulin therapy for type 2 diabetes.

Authors: Sanne G Swinnen; Joost B Hoekstra; J Hans DeVries
Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112

6. Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.

Authors: Angus G Jones; Timothy J McDonald; Beverley M Shields; Anita V Hill; Christopher J Hyde; Bridget A Knight; Andrew T Hattersley
Journal: Diabetes Care Date: 2015-08-04 Impact factor: 19.112

7. Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.

Authors: Andrew Ahmann
Journal: Drugs Context Date: 2015-11-11

8. Characterization of a novel glucokinase activator in rat and mouse models.

Authors: Min Lu; Pingping Li; Gautam Bandyopadhyay; William Lagakos; Walter E Dewolf; Taylor Alford; Mark Joseph Chicarelli; Lance Williams; Deborah A Anderson; Brian R Baer; Maralee McVean; Marion Conn; Murielle M Véniant; Peter Coward
Journal: PLoS One Date: 2014-02-12 Impact factor: 3.240

9. Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.

Authors: Joshua J Neumiller
Journal: Clin Diabetes Date: 2014-10

10. Reported Benefits of Insulin Therapy for Better Glycemic Control in Type 2 Diabetic Patients-Is This Applicable in Saudi Patients?

Authors: Wafaa AlSaggaf; Mohammed Asiri; Balgees Ajlan; Alaa Bin Afif; Roaa Khalil; Anas Bin Salman; Ahmed Alghamdi; Osama Bashawieh; Atheer Alamoudi; Abeer Aljahdali; Nouf Aljahdali; Hussam Patwa; Mohammed Bakhaidar; Suhad M Bahijri; Maimoona Ahmed; Khalid Al-Shali; Samia Bokhari; Amani Alhozali; Anwar Borai; Ghada Ajabnoor; Jaakko Tuomilehto
Journal: Clin Med Insights Endocrinol Diabetes Date: 2016-06-08